This is a preview of subscription content, log in via an institution to check access.
References
Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? PharmacoEconomics 1996; 9(6): 484–96
Wynne HA, Campbell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). PharmacoEconomics 1994; 3(2): 107–23
British National Formulary. No. 31. London: The Pharmaceutical Press. 1996 Mar: 403–12
Office of Health Economics. Arthritis. London: Office of Health Economics, 1992
Committee on the Safety of Medicines (CSM). Relative safety of oral non-aspirin NSAIDs: current problems in pharmacovigilence. London: CSM/Medicines Control Agency, 1994: 20
Maiden N, Madhok R. Misoprostol in patients taking non-steroidal anti-inflammatory drugs: best reserved for elderly patients at high risk. BMJ 1995; 311: 1518–9
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9
Rights and permissions
About this article
Cite this article
What scope is there for improving the cost effectiveness of NSAIDs?. Drugs Ther. Perspect 8, 12–16 (1996). https://doi.org/10.2165/00042310-199608090-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199608090-00005